Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=44 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
HIV-1 Infection · Hepatitis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 58.8; 100.0 Percentage of participants
Phase 2 N=45 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Hepatitis C Infection · HIV Infection
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment Discontinuation (SVR12) — 84.4 percentage of participants
Phase 3 N=286 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Hepatitis C Virus (HCV)
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) Population — 96.2 percentage of…
Phase 2 N=30 Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
Acute Hepatitis C · HIV
Primary: Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 28 Participants
Phase 3 N=80 Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV
Acute Hepatitis C · Human Immunodeficiency Virus · Hepatitis C
Primary: SVR12 (Reinfection Not Considered Failure) — 79 participants
N/A N=366 Undiagnosed Hepatitis C Infection in an Urban Hospital
Hepatitis C
Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects
Phase 3 N=130 Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)
Hepatitis C
Primary: Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period — 23; 20; 21 participants
N/A N=21 Hepatitis C Virus (HCV) Treatment Completion or Withdrawal
Hepatitis C
Primary: Attributes of Treatment Experience — 14; 15; 7; 9 participants
Phase 4 N=600 Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
HCV HIV
Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants
N/A N=68 Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
HIV · Hepatitis C, Chronic
Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036
Phase 3 N=188 Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
Hepatitis C
Primary: Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) Following SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent…
Phase 2 N=72 Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Chronic Hepatitis C
Primary: Number of Participants With Sustained Virologic Response — 70 Participants
N/A N=134 Hepatitis C Self-Management
Hepatitis C · Chronic Disease
Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale
Phase 2 N=548 Staged Phase I/II Hepatitis C Prophylactic Vaccine
Hepatitis C
Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317
Phase 1 N=31 Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
Chronic Hepatitis C Infection
Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Phase 4 N=10 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
Phase 4 N=14 DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)
Hepatitis C, Chronic
Primary: SVR12 (Sustain Virological Response, HCV RNA Undetectable 12 Weeks Post-treatment) — 71; 100; 100 percentage of participants
Phase 4 N=10 Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Chronic Kidney Disease · Chronic Hepatitis C
Primary: Average Change in Urine Tumor Necrosis Factor (TNF)-Alpha From Baseline to Post-treatment — -0.05 ng/g
Phase 2 N=21 High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
Chronic Hepatitis C
Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants
N/A N=49 A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR): Percentage of Participants Who Were HCV Seronegative at 6 Months After Completing Therapy — 59.5; 58.3 percentage of participants
N/A N=309 Hepatitis C Translating Initiatives for Depression Into Effective Solutions
Hepatitis C · Depression
Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants
Phase 2 N=19 Herpes Simplex Type 1 Suppression in Hepatitis C
Chronic Hepatitis C Infection
Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05
Phase 1 N=5 Viral Kinetics in HCV Clearance in Subjects With Hemophilia
Chronic Hepatitis C · Hemophilia
Primary: Number of Participants With Sustained Virological Response at Week 12 (SVR12) — 2; 2 participants
Phase 2 N=229 Combination Therapy for Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
Phase 1 N=20 Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
Hepatitis, Chronic · Hepatitis C Virus
Primary: Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set — 6.11; -0.45 log10 IU/mL
Phase 2 N=57 Dutch Acute HCV in HIV Study (DAHHS)
Hepatitis C · Human Immunodeficiency Virus
Primary: Sustained Viral Response(SVR) 12 Weeks of Follow up After the End of All Therapy for the Rapid Viral Response at Week 4(RVR4) Population. — 41 participants
N/A N=33,808 An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C
Hepatitis C, Chronic
Primary: Incidence of Acute Myocardial Infarction (AMI) — 3.3; 5.2 Events per 1000 person years — p=.68
Phase 2 N=30 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
HIV-HCV
Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects